Brief: Sensorion H1 Net Loss Narrows To 5.5 Million Euros

Sensorion SA

31/10/2019 06:48

Oct 31 (Reuters) - Sensorion SA  ALSEN.PA :
    * SENSORION REPORTS ITS 2019 FIRST HALF RESULTS
    * H1 FINANCIAL POSITION STRENGTHENED WITH ISSUANCE OF A EUR
20M
MANDATORY CONVERTIBLE BOND
    * WE ESTIMATE THAT CASH IN HAND WILL CARRY US THROUGH MIDDLE
OF Q1
OF 2021
    * CASH POSITION OF EUR 22.3M AT JUNE 30 2019
    * WE EXPECT SENS-111 PHASE 2 CLINICAL RESULTS BEFORE YEAR
END
    * OPERATING LOSS AT JUNE 30 2019 THUS AMOUNTED TO -EUR 5.4M,
COMPARED WITH -EUR 6.09M AT JUNE 30 2018
    * H1 NET LOSS EUR 5.5 MILLION VERSUS LOSS EUR 6.1 MILLION
YEAR AGO
    * RESULTS OF POC PHASE 2 STUDY ON SENS-111 EFFICACY IN ACUTE
UNILATERAL VESTIBULOPATHY ARE EXPECTED BY END OF YEAR
    * PROCEEDS FROM CAPITAL INCREASE TO BE USED TO FINANCE THE
PHASE 2
CLINICAL PROGRAM FOR SENS-111, SENS-401, AND THE PRECLINICAL
GENE THERAPY PROGRAMS
    * SENS-401 PHASE 2 INTERIM SAFETY RESULTS IN SUDDEN HEARING
LOSS
(SSNHL) TO BE RELEASED BY END OF YEAR 2019 AND TOP LINE READ OUT
ANTICIPATED AT END OF H1 2020

Source text for Eikon:  ID:nBw1SG7MMa 
Further company coverage:  ALSEN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))